Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to johnstevens77,Bhoddhisatva,scotia,Anonymous,Cornytiv34, for Donating to support the site

GlaxoSmithKline PLC (GSK)

Share latest information on individual companies and hot news discussions. LSE Main Market companies only
Forum rules
No penny shares or promotional posts
daveh
Lemon Quarter
Posts: 2191
Joined: November 4th, 2016, 11:06 am
Has thanked: 409 times
Been thanked: 807 times

Re: GlaxoSmithKline PLC (GSK)

#412778

Postby daveh » May 17th, 2021, 5:35 pm

Gengulphus wrote:
idpickering wrote:Sanofi/GSK COVID-19 Vaccine Positive Ph2 Results

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

· Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups

· High immune response after a single dose in patients with prior infection shows strong booster potential

· Global Phase 3 study expected to start in the coming weeks

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.

The Phase 2 interim results showed 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old) and across all doses, with acceptable tolerability and with no safety concerns. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old). After a single injection, high neutralizing antibody levels were generated in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine.

https://www.investegate.co.uk/glaxosmit ... 00098031Y/

This is obviously good news for the company, and also for the world (the total number of vaccine doses given so far is only about 9% of the number required to give everyone in the world two doses, so there's a lot of vaccinations still to be done). But even assuming that everything goes well from here on, there are still months of phase 3 clinical trials to go, plus the time required for national authorities to approve it, so GSK is probably the best part of a year late to the COVID-19 market. That severely limits how good the news will be for GSK even if all goes well from here on - by the time their vaccine is available for actual use, most of the better-off countries will be approaching full vaccination (*), so I think they'll mainly be supplying vaccines to countries that can only afford lower prices.

So I think it's likely to prove better news for the world than for GSK itself...

Gengulphus


The interesting bit for me is that they are already testing two variants (Wuhan original and South African) and they are planning to test multiple variants with the aim of giving booster jags for variants to people who have had the full course of other companies vaccines - so they could have large market in the developed countries that are already well into their vaccination program.

The Phase 3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants.



In parallel, the Companies intend to conduct booster studies with various variant formulations in order to assess the ability of a lower dose of the vaccine to generate a strong booster response regardless of the initial vaccine platform received.

johnstevens77
Lemon Slice
Posts: 440
Joined: November 9th, 2016, 6:14 pm
Has thanked: 421 times
Been thanked: 147 times

Re: GlaxoSmithKline PLC (GSK)

#412786

Postby johnstevens77 » May 17th, 2021, 5:54 pm

monabri wrote:I bet that this vaccine will be widely adopted by our "friends" in France...especially as it is Sanofi. ;)

I read this in Figaro today, no mention of GSK!

johm

monabri
Lemon Half
Posts: 8396
Joined: January 7th, 2017, 9:56 am
Has thanked: 1539 times
Been thanked: 3428 times

Re: GlaxoSmithKline PLC (GSK)

#412806

Postby monabri » May 17th, 2021, 7:02 pm

In the French version they say

"Le laboratoire français Sanofi a publié lundi des résultats positifs d'un essai clinique sur son principal candidat-vaccin contre le Covid-19, développé avec le britannique GSK, après un revers qui avait occasionné plusieurs mois de retard".


I'm surprised that they mentioned the British contribution...it was probably our fault that we slowed them down, eh?

tjh290633
Lemon Half
Posts: 8208
Joined: November 4th, 2016, 11:20 am
Has thanked: 913 times
Been thanked: 4096 times

Re: GlaxoSmithKline PLC (GSK)

#412935

Postby tjh290633 » May 18th, 2021, 11:23 am

Another one today:

https://www.investegate.co.uk/glaxosmit ... 00029624Y/

Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

· Similar antibody response in adults and in the elderly after two doses

· Neutralizing antibody responses were ten times higher than in people recovering from COVID-19

· No related severe adverse events reported


TJH

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithKline PLC (GSK)

#415449

Postby idpickering » May 27th, 2021, 7:22 am

GSK/Vir Sotrovimab FDA Emergency Use Authorization

https://www.investegate.co.uk/glaxosmit ... 00019627Z/

Sanofi and GSK initiate new Phase 3 clinical study

https://www.investegate.co.uk/glaxosmit ... 00010099A/

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithKline PLC (GSK)

#421321

Postby idpickering » June 22nd, 2021, 7:11 am

ViiV/Halozyme sign exclusive licensing agreement

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra long-acting" medicines for HIV


https://www.investegate.co.uk/glaxosmit ... 00036201C/

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithKline PLC (GSK)

#424034

Postby idpickering » July 1st, 2021, 4:46 pm

This item from TMF might be of interest to some hereabouts;

Is GlaxoSmithKline stock a buy or sell?

The GlaxoSmithKline (LSE:GSK) share price is up almost 1% today. Yesterday, Elliot Management, an activist investor, published an open letter to the Board of Directors of Glaxo. In the letter, Elliott outlined its rationale for taking a stake in Glaxo and what changes it wants to see.

What Elliott Management wants

On page two of the letter, Elliott presents a rather bleak summary of Glaxo shareholder’s returns. According to the table, over 10 years, Glaxo has underperformed its peers in total shareholder return by 210% on average. A particularly sour note for Glaxo shareholders might be the charge that shares in British rival AstraZeneca outperformed Glaxo’s by 166% over a decade.


Later on the author pretty much sums up my opinion regarding GSK, and the future of it (them) here;

Overall, I think the split will be positive for Glaxo’s stock price in the long run. I agree with Elliott’s view on sentiment and the need for a management shakeup. I continue to buy Glaxo stock for my portfolio.


https://www.fool.co.uk/investing/2021/0 ... y-or-sell/

I topped up my GSK holdings this January, and February, and intend sticking with GSK for the long term.

Ian.

daveh
Lemon Quarter
Posts: 2191
Joined: November 4th, 2016, 11:06 am
Has thanked: 409 times
Been thanked: 807 times

Re: GlaxoSmithKline PLC (GSK)

#424237

Postby daveh » July 2nd, 2021, 1:32 pm

GSK have now replied to Elliot's letter here:
https://www.investegate.co.uk/glaxosmit ... 41550149E/

The Board of GSK notes the letter issued by Elliott Advisors (UK) Limited ("Elliott") on 1 July. The Board welcomes constructive input from all shareholders that is supportive of the creation and delivery of long-term sustainable shareholder value and benefits for patients. The Board is issuing this announcement to all shareholders and all parties with an interest in GSK to address the matters raised by Elliott in the letter.


and are to collaborate with Alector in Immuno-neurology

https://www.investegate.co.uk/glaxosmit ... 36490449E/

GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases



· GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease

· Companies will co-commercialise and share profits in the US; GSK will retain exclusive commercialisation rights outside the US

· Alector will receive $700 million in upfront payments, up to $1.5 billion in potential milestone payments, profit sharing and royalties

dealtn
Lemon Half
Posts: 6072
Joined: November 21st, 2016, 4:26 pm
Has thanked: 441 times
Been thanked: 2324 times

Re: GlaxoSmithKline PLC (GSK)

#424279

Postby dealtn » July 2nd, 2021, 4:51 pm

idpickering wrote:This item from TMF might be of interest to some hereabouts;

Is GlaxoSmithKline stock a buy or sell?

The GlaxoSmithKline (LSE:GSK) share price is up almost 1% today. Yesterday, Elliot Management, an activist investor, published an open letter to the Board of Directors of Glaxo. In the letter, Elliott outlined its rationale for taking a stake in Glaxo and what changes it wants to see.

What Elliott Management wants

On page two of the letter, Elliott presents a rather bleak summary of Glaxo shareholder’s returns. According to the table, over 10 years, Glaxo has underperformed its peers in total shareholder return by 210% on average. A particularly sour note for Glaxo shareholders might be the charge that shares in British rival AstraZeneca outperformed Glaxo’s by 166% over a decade.


Later on the author pretty much sums up my opinion regarding GSK, and the future of it (them) here;

Overall, I think the split will be positive for Glaxo’s stock price in the long run. I agree with Elliott’s view on sentiment and the need for a management shakeup. I continue to buy Glaxo stock for my portfolio.


https://www.fool.co.uk/investing/2021/0 ... y-or-sell/

I topped up my GSK holdings this January, and February, and intend sticking with GSK for the long term.

Ian.


Why read a tip sheet's view on an investor's open letter to shareholders as news when you can read that open letter itself.

https://www.elliottmaterials.com/~/medi ... 072021.pdf

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithKline PLC (GSK)

#424281

Postby idpickering » July 2nd, 2021, 5:27 pm

dealtn wrote:
idpickering wrote:This item from TMF might be of interest to some hereabouts;

Is GlaxoSmithKline stock a buy or sell?

The GlaxoSmithKline (LSE:GSK) share price is up almost 1% today. Yesterday, Elliot Management, an activist investor, published an open letter to the Board of Directors of Glaxo. In the letter, Elliott outlined its rationale for taking a stake in Glaxo and what changes it wants to see.

What Elliott Management wants

On page two of the letter, Elliott presents a rather bleak summary of Glaxo shareholder’s returns. According to the table, over 10 years, Glaxo has underperformed its peers in total shareholder return by 210% on average. A particularly sour note for Glaxo shareholders might be the charge that shares in British rival AstraZeneca outperformed Glaxo’s by 166% over a decade.


Later on the author pretty much sums up my opinion regarding GSK, and the future of it (them) here;

Overall, I think the split will be positive for Glaxo’s stock price in the long run. I agree with Elliott’s view on sentiment and the need for a management shakeup. I continue to buy Glaxo stock for my portfolio.


https://www.fool.co.uk/investing/2021/0 ... y-or-sell/

I topped up my GSK holdings this January, and February, and intend sticking with GSK for the long term.

Ian.


Why read a tip sheet's view on an investor's open letter to shareholders as news when you can read that open letter itself.

https://www.elliottmaterials.com/~/medi ... 072021.pdf


I didn't know the open letter existed. That's all. Not sure I like your tone tbh.

Ian.

dealtn
Lemon Half
Posts: 6072
Joined: November 21st, 2016, 4:26 pm
Has thanked: 441 times
Been thanked: 2324 times

Re: GlaxoSmithKline PLC (GSK)

#424285

Postby dealtn » July 2nd, 2021, 6:13 pm

idpickering wrote:
I didn't know the open letter existed. That's all. Not sure I like your tone tbh.

Ian.


Odd given it was quoted and linked to in the piece you provided that you thought might be of interest. Literally in sentences 2 and 3. I assumed you would at least have read the article your own link takes the reader to.

Regardless, I was trying to direct "readers" to "read" the underlying piece, or the News, given the Board we are on, and provided that link as an easy route to do so. Maybe if I had played the man and said "Why post a tip sheet's view ... " in a passive aggressive manner you, or a moderator, would correct such an ad hominem disregard for the site rules.

If I'm honest one of the reasons I am a less frequent visitor to this is the general feeling of unfriendliness you can frequently encounter here. Or "tone" if you like. I tend now to only seek the Company Share news, or Share idea boards, for hopefully genuinely investment related news or ideas, amongst the increasing politics and factions on numerous other Boards. The number of posts, and posters appears to be in decline on those boards sadly. I think I have only made this single post in the last few weeks, yet in a short time of doing so I get thanked once, and mildly admonished in equal measure.

I worry my opinion of the direction of the site generally might be summed up in that statistic. I'm certainly less inclined to visit, or contribute, than I used to.

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithKline PLC (GSK)

#424292

Postby idpickering » July 2nd, 2021, 7:22 pm

dealtn wrote:
idpickering wrote:
I didn't know the open letter existed. That's all. Not sure I like your tone tbh.

Ian.


Odd given it was quoted and linked to in the piece you provided that you thought might be of interest. Literally in sentences 2 and 3. I assumed you would at least have read the article your own link takes the reader to.

Regardless, I was trying to direct "readers" to "read" the underlying piece, or the News, given the Board we are on, and provided that link as an easy route to do so. Maybe if I had played the man and said "Why post a tip sheet's view ... " in a passive aggressive manner you, or a moderator, would correct such an ad hominem disregard for the site rules.

If I'm honest one of the reasons I am a less frequent visitor to this is the general feeling of unfriendliness you can frequently encounter here. Or "tone" if you like. I tend now to only seek the Company Share news, or Share idea boards, for hopefully genuinely investment related news or ideas, amongst the increasing politics and factions on numerous other Boards. The number of posts, and posters appears to be in decline on those boards sadly. I think I have only made this single post in the last few weeks, yet in a short time of doing so I get thanked once, and mildly admonished in equal measure.

I worry my opinion of the direction of the site generally might be summed up in that statistic. I'm certainly less inclined to visit, or contribute, than I used to.


Fair enough. Please accept a thanks from me.

Ian.

monabri
Lemon Half
Posts: 8396
Joined: January 7th, 2017, 9:56 am
Has thanked: 1539 times
Been thanked: 3428 times

Re: GlaxoSmithKline PLC (GSK)

#429774

Postby monabri » July 22nd, 2021, 10:00 pm

https://www.investegate.co.uk/glaxosmit ... 45071817G/

"The Board of GSK (GSK) today announces that Brian McNamara, the CEO of GSK Consumer Healthcare (a Joint Venture between GSK and Pfizer) has been appointed as CEO Designate of the new, listed Consumer Healthcare company which will result from the proposed demerger of Consumer Healthcare from GSK in 2022."

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithKline PLC (GSK)

#432709

Postby idpickering » August 5th, 2021, 4:37 pm

GlaxoSmithKline wins $235M from Teva in carve-out patent fight over heart drug.

GlaxoSmithKline’s heart drug Coreg has been around a good long while, but it still pumps out more revenue for the U.K. drug company to keep fighting patent battles for the drug. Teva now finds itself on the losing end of one of those fights in another carve-out patent battle.

A federal jury in Delaware has awarded GSK $235 million in a suit in which it found that Teva had infringed GSK’s drug by marketing its generic as a treatment for chronic heart failure, as well as high blood pressure, Reuters reports.

The award included $234.1 million in lost profits and said GSK deserved an additional $1.4 million in royalties. Teva told the news service that it's considering whether to appeal but still has pending an “equitable defenses” filing that could reduce the award.

Coreg, which generated $131 million for GSK last year, has been around since about 1995. It is approved for treating a number of conditions, including congestive heart failure. Teva’s generic when approved had a so-called carve-out for CHF, which essentially allows copies of a drug to launch for particular uses while one or more indication is still covered by a method-of-use patent.

GSK contended that Teva induced healthcare providers to infringe that patent by marketing its drug for congestive heart failure as well as its approved uses, and the jury agreed.

Carve-outs where the FDA approves a generic only for particular indications have complicated patent protections for drugmakers. Last year, Pfizer lost a closely watched carve-out case in the U.K. for its $5.1 billion blockbuster med Lyrica that is not unlike the GSK case in the U.S.


https://www.fiercepharma.com/legal/gsk- ... heart-drug

TheMotorcycleBoy
Lemon Quarter
Posts: 3245
Joined: March 7th, 2018, 8:14 pm
Has thanked: 2222 times
Been thanked: 587 times

Re: GlaxoSmithKline PLC (GSK)

#434867

Postby TheMotorcycleBoy » August 15th, 2021, 11:35 am

monabri wrote:https://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/ceo-designate-of-new-consumer-healthcare-company/202107221445071817G/

"The Board of GSK (GSK) today announces that Brian McNamara, the CEO of GSK Consumer Healthcare (a Joint Venture between GSK and Pfizer) has been appointed as CEO Designate of the new, listed Consumer Healthcare company which will result from the proposed demerger of Consumer Healthcare from GSK in 2022."

Also from same RNS:

As set out at GSK's Investor Update on 23 June 2021, subject to approval from shareholders, the separation of Consumer Healthcare will be by way of a demerger in mid-2022 of at least 80% of GSK's holding to shareholders. The new resulting Consumer Healthcare company is expected to attain a premium listing on the London Stock Exchange.

therefore only 20% of equity value in the "high margin" pharma company (The excitingly branded New GSK).

Matt

EDIT the SP is up 6% over past month - perhaps the market appreciates the sounds

scrumpyjack
Lemon Quarter
Posts: 4812
Joined: November 4th, 2016, 10:15 am
Has thanked: 605 times
Been thanked: 2675 times

Re: GlaxoSmithKline PLC (GSK)

#434868

Postby scrumpyjack » August 15th, 2021, 11:42 am

TheMotorcycleBoy wrote:
monabri wrote:https://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/ceo-designate-of-new-consumer-healthcare-company/202107221445071817G/

therefore only 20% of equity value in the "high margin" pharma company (The excitingly branded New GSK).

Matt


Not sure what you mean by that. What I think it means is that GSK is distributing shares in the Consumer Healthcare Business to shareholders and retaining some shares itself, but less than 20%. Holding less than 20% avoids accounting complications. They can them sell those shares when they need to raise cash for the pharma business.

It is not a comment on the respective value of the Pharma business as opposed to the Consumer Healthcare business.

TheMotorcycleBoy
Lemon Quarter
Posts: 3245
Joined: March 7th, 2018, 8:14 pm
Has thanked: 2222 times
Been thanked: 587 times

Re: GlaxoSmithKline PLC (GSK)

#434872

Postby TheMotorcycleBoy » August 15th, 2021, 11:49 am

https://www.investegate.co.uk/glaxosmit ... 00017647G/

Emma likes the outlook implied by their Q2. Well enough for her to use the word performance 3x in one short paragraph:

GSK delivered an excellent performance in Q2. We expect this positive momentum to continue through the second half of the year driving us towards the better end of our earnings guidance range for 2021, and meaningful performance improvement in 2022. We continue to strengthen our pipeline and are advancing well towards separation. Our clear priority is to focus on execution, unlocking the value of Consumer Healthcare and delivering the step-change in growth and performance we now see for GSK.

TheMotorcycleBoy
Lemon Quarter
Posts: 3245
Joined: March 7th, 2018, 8:14 pm
Has thanked: 2222 times
Been thanked: 587 times

Re: GlaxoSmithKline PLC (GSK)

#434876

Postby TheMotorcycleBoy » August 15th, 2021, 12:00 pm

scrumpyjack wrote:
TheMotorcycleBoy wrote:
monabri wrote:https://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/ceo-designate-of-new-consumer-healthcare-company/202107221445071817G/

therefore only 20% of equity value in the "high margin" pharma company (The excitingly branded New GSK).

Matt


Not sure what you mean by that. What I think it means is that GSK is distributing shares in the Consumer Healthcare Business to shareholders and retaining some shares itself, but less than 20%. Holding less than 20% avoids accounting complications. They can them sell those shares when they need to raise cash for the pharma business.

It is not a comment on the respective value of the Pharma business as opposed to the Consumer Healthcare business.

Apologies, perhaps I've misunderstood this sentence:

demerger in mid-2022 of at least 80% of GSK's holding to shareholders

that looks like their way of saying 80% of the total value of GSK equity goes into the new firm. In other words, suppose my portfolio breakdown includes this line currently the day before the demerger


then by applying my literal interpretation the italicised as quoted from RNS, then I'd expect the following two lines in the breakdown on the day of the demerger.


That's all.

Matt

scrumpyjack
Lemon Quarter
Posts: 4812
Joined: November 4th, 2016, 10:15 am
Has thanked: 605 times
Been thanked: 2675 times

Re: GlaxoSmithKline PLC (GSK)

#434883

Postby scrumpyjack » August 15th, 2021, 12:25 pm

No I'm sure it means 80% of GSK's holding in GSK Consumer Healthcare. Nothing to do with the valuation of the two businesses.

Confirmed by this article in Forbes

https://www.forbes.com/sites/joecornell ... 7fb8c372d0

BT63
Lemon Slice
Posts: 432
Joined: November 5th, 2016, 1:22 pm
Has thanked: 59 times
Been thanked: 121 times

Re: GlaxoSmithKline PLC (GSK)

#434886

Postby BT63 » August 15th, 2021, 12:31 pm

scrumpyjack wrote:What I think it means is that GSK is distributing shares in the Consumer Healthcare Business to shareholders and retaining some shares itself, but less than 20%. Holding less than 20% avoids accounting complications. They can them sell those shares when they need to raise cash for the pharma business.

It is not a comment on the respective value of the Pharma business as opposed to the Consumer Healthcare business.



This is also how I interpret what they said.
GSK will retain 20% ownership of the consumer business, just as many other companies have cross-holdings of shares in other companies or joint ventures.


Return to “Company Share news (LSE Main Market)”

Who is online

Users browsing this forum: No registered users and 9 guests